权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

RECOMBINANT DNA DIAGNOSTIC PROBES FOR SMALL CELL CANCERS

小细胞癌重组 DNA 诊断探针

基本信息

批准号：
3181283
负责人：
WINSTON SALSER
金额：
$ 11.16万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
1985
资助国家：
美国
起止时间：
1985-09-30 至 1989-07-31
项目状态：
已结题

项目摘要

We will use recombinant DNA technology to select cDNA clones that can improve diagnosis of small cell tumors. These cancers include oat cell carcinoma, many of the non-Hodgkin's lymphomas, Ewing's sarcoma, small cell tumors of neuroectodermal origin, embryonal rhabdomyosarcoma, and the leukemias. In many cases the tumor cells are primitive cells which may be difficult to classify because there is no evidence of features of maturation. Yet proper classification is important since treatment is often different depending upon the cell type of the tissue of origin for the malignant cells. It is now possible to use recombinant DNA techniques to create hybridization probes, which can assay mRNA species present in one cell type and not another. In theory, immunodiagnostic approaches also are capable of assaying any gene product in which two malignant cell types may differ, but only recombinant DNA techniques offer the ability to efficiently select the crucial gene product even if it is a rare mRNA species unique to only one of the two cell types. In earlier work we selected a panel of clones corresponding to abundant mRNAs strongly regulated during myeloid differentiation. These clones will be useful in distinguishing between myeloid and lymphoid cells. We expect that some members of this panel of clones may also be useful in distinguishing any hematopoietic cell from cells of other lineages. We will use the new hybridization-subtraction recombinant DNA technology to select additional cDNA clones which can improve the differential diagnosis of the small cell tumors. This approach, if successful, will improve subclassification of other cancer cell types so that the most effective treatment can be selected. (2)

我们将使用重组DNA技术来选择cDNA克隆，改善小细胞肿瘤诊断。这些癌症包括燕麦细胞癌，许多非霍奇金淋巴瘤，尤文肉瘤，小细胞神经外胚层起源的肿瘤，胚胎性横纹肌肉瘤，以及白血病在许多情况下，肿瘤细胞是原始细胞，可能很难分离分类，因为没有证据表明成熟的特征。然而正确的分类是很重要的，因为治疗往往是不同的根据恶性肿瘤起源组织的细胞类型，细胞现在可以使用重组DNA技术来创造杂交探针，其可以测定存在于一种细胞类型中的mRNA种类而不是另一个理论上，免疫诊断方法也能够分析任何两种恶性细胞类型可能不同的基因产物，但只有重组DNA技术才能有效地选择关键的基因产物，即使它是一种罕见的mRNA物种，只有两种细胞类型之一在早期的工作中，我们选择了一组对应于丰富的在骨髓分化过程中，mRNA受到强烈调控。这些克隆人将可用于区分骨髓细胞和淋巴细胞。我们预计这组克隆体中的一些成员也可能有助于将任何造血细胞与其他谱系的细胞区分开。我们将利用新的杂交-消减重组DNA技术，选择可改善鉴别诊断的额外cDNA克隆小细胞肿瘤。这种方法如果成功，其他癌细胞类型的亚分类，使最有效的可以选择治疗。（二）